Throughout the 6 weeks I spent researching the design and synthesis of this compound, I have concluded that O-(4-methyl)-phenyl-N-(9’-acrdinyl)-hydroxylamine can successfully be synthesized in a proper lab setting in which more resources are available and more time is given. Due to a lack of time and materials, I was not able to completely synthesize O-(4-methyl)-phenyl-N-(9’-acrdinyl)-hydroxylamine, however if this experiment was repeated, it could be completed. Some errors in this experiment include not following the procedure exactly. This includes allowing any of the reactions to sit for too long or allowing an unstable product to sit for long. Several of the errors made in this research project consisted of human errors that can easily be fixed.
Future studies, if the compound can successfully be synthesized, would take place over a series of years. The next step after the series of experiments would be to consistently produce the compound successfully with high enough yields in which it would be cost efficient and feasible. Next, the compound would be tested on plates of cancer cells to see if the side effects are as expected. It would also be tested to see if any new side effects and unintended consequences form. If the previous procedures are successful, then the drug would be tested on rodents, small mammals, then primates, and then would eventually lead to clinical testing.
Future studies, if the compound can successfully be synthesized, would take place over a series of years. The next step after the series of experiments would be to consistently produce the compound successfully with high enough yields in which it would be cost efficient and feasible. Next, the compound would be tested on plates of cancer cells to see if the side effects are as expected. It would also be tested to see if any new side effects and unintended consequences form. If the previous procedures are successful, then the drug would be tested on rodents, small mammals, then primates, and then would eventually lead to clinical testing.